Research To Practice | Oncology Videos

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Targeted Therapy for Non-Small Cell Lung Cancer — Faculty Presentation 1: Management of Non-Small Cell Lung Cancer with an EGFR, ALK or ROS1 Abnormality — Dr Zofia Piotrowska CME information and select publications

Featuring perspectives from Drs Zofia Piotrowska and Gregory Riely, including the following topics: Introduction: What Is Targeted Therapy? (0:00) EGFR-Activating Mutations (12:23) EGFR Exon 20 Insertion Mutations (27:54) ALK and ROS1 Rearrangements (31:31) HER2 Mutations (36:17) NRG1 Fusions (45:39) RET Fusions (49:07) MET Exon 14 Mutations (53:10) KRAS G12C Mutations (56:01) CME information and...

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Chronic Lymphocytic Leukemia — Faculty Presentation 2: Treatment of Relapsed/Refractory CLL; Novel and Investigational Strategies — Dr Deborah Stephens CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Chronic Lymphocytic Leukemia — Faculty Presentation 1: Optimizing the First-Line Management of Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) — Dr Jennifer Brown CME information and select publications

Featuring perspectives from Drs Jennifer Brown and Deborah Stephens, including the following topics: Introduction: First-Line Treatment of Chronic Lymphocytic Leukemia (0:00) Combining Bruton Tyrosine Kinase (BTK) Inhibitors with Venetoclax; Venetoclax Consolidation (36:57) Noncovalent BTK Inhibitors; Pirtobrutinib (42:59) CAR T-Cell Therapy; Lisocabtagene Maraleucel (51:26) Richter's Transformati...

Featuring perspectives from Dr Shaji Kumar, including the following topics: Introduction (0:00) Case: A woman in her early 70s with standard-risk newly diagnosed multiple myeloma (NDMM), "borderline transplant-eligible," receiving daratumumab-RVd, with transportation limitations and missed treatments — Neil Morganstein, MD (11:50) Case: A woman in her early 50s with Stage III, high-risk NDMM (1q21...

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Breast Cancer — Faculty Presentation 2: Metastatic Breast Cancer — Dr Joyce O'Shaughnessy CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Breast Cancer — Faculty Presentation 1: Localized Breast Cancer — Professor Peter Schmid CME information and select publications

Featuring perspectives from Dr Joyce O'Shaughnessy and Prof Peter Schmid, including the following topics: Introduction: POSITIVE Trial — Temporary Interruption of Endocrine Therapy for Pregnancy (0:00) Metastatic Breast Cancer — Dr O'Shaughnessy (7:44) Localized Breast Cancer — Prof Schmid (41:25) CME information and select publications

Featuring perspectives from Drs Courtney DiNardo and Mark Levis, including the following topics: Introduction (0:00) Case: A man in his early 80s with newly diagnosed acute myeloid leukemia (AML) with significant comorbidities receives decitabine/venetoclax — Rebecca L Olin, MD, MSCE (7:36) Cases: A man in his mid 50s after 7 + 3 and allogeneic stem cell transplantation (SCT) presents with myeloid...

What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Acute Myeloid Leukemia — Faculty Presentation 1: Selection of Therapy for Older and Younger Patients with Acute Myeloid Leukemia (AML) — Dr Courtney DiNardo CME information and select publications

What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Acute Myeloid Leukemia — Faculty Presentation 2: Treatment of AML with Targetable Mutations — Dr Andrew Wei CME information and select publications

Featuring an interview with Dr Manish Shah, including the following topics: Biologic rationale for targeting PD-1/PD-L1 in upper GI cancers (0:00) Management of HER2-positive gastric cancers (6:38) Activity and tolerability of therapies targeting claudin 18.2 for patients with GI malignancies (15:48) CME information and select publications

Featuring an interview with Dr Manish Shah, including the following topics: Role of targeted and immunotherapy regimens for upper GI cancers (0:00) Future of CAR T-cell therapy for patients with gastric cancer (11:26) Case: A man in his mid 60s with HER2-positive gastroesophageal adenocarcinoma (15:59) Case: A woman in her mid 70s with newly diagnosed HER2-negative, pMMR gastric cancer (29:57) Cas...

Featuring perspectives from Drs Jesús Berdeja, Rafael Fonseca, Sagar Lonial, Robert Orlowski and Noopur Raje, including the following topics: Front-Line Treatment of Multiple Myeloma (MM)  Introduction (0:00) Case: A woman in her early 50s with newly diagnosed MM (NDMM) and 1q gain who presents with a pathologic fracture and receives daratumumab/RVd — Bhavana (Tina) Bhatnagar, DO (2:49) Cases: An...

Featuring perspectives from Drs Jonathan Friedberg, Brad Kahl, David Maloney, Loretta Nastoupil and Sonali Smith, including the following topics: Diffuse Large B-Cell Lymphoma (DLBCL)  Introduction (0:00) Case: A woman in her early 60s with DLBCL with renal and subcutaneous involvement — Erik Rupard, MD (2:36) Cases: An otherwise healthy woman in her mid 80s with an orbital mass diagnosed with Sta...

Featuring a slide presentation and related discussion from Dr Scott Tagawa, including the following topics: Managing patients with FGFR-altered urothelial bladder cancer (UBC) (0:00) Antibody-drug conjugates as treatment for metastatic UBC (10:22) Strategies for using systemic therapies to treat metastatic UBC (27:31) CME information and select publications

Featuring an interview with Dr Scott Tagawa, including the following topics: Sequencing therapies for patients with metastatic urothelial bladder cancer (UBC) (0:00) Case: A man in his mid 80s with UBC with multiple lung and lymph node metastases (4:55) Case: A woman in her mid 80s with metastatic UBC who is undergoing treatment with erdafitinib (46:21) Case: A man in his mid 60s with FGFR-altered...

Featuring perspectives from Drs Aditya Bardia, Matthew Goetz, Virginia Kaklamani, Kevin Kalinsky and Hope Rugo, including the following topics: Current Role of Genomic Assays for Hormone Receptor (HR)-Positive Localized Breast Cancer  Introduction (0:00) Case: A premenopausal woman in her early 40s with 9-mm, Grade III, ER/PR-positive, HER2-negative, node-negative infiltrating ductal carcinoma (ID...

Featuring perspectives from Drs Alexey Danilov, Matthew Davids, Lindsey Roeker, Philip Thompson and Prof Dr Arnon Kater, including the following topics: Front-Line Treatment of Chronic Lymphocytic Leukemia (CLL)   Introduction (0:00) Cases: A man in his early 90s with Rai Stage 0 CLL who underwent surveillance x 5 years and now develops cytopenias and transfusion-dependent anemia, and a woman in h...

Featuring perspectives from Drs Erika Hamilton, Sara Hurvitz, Ian Krop, Shanu Modi and Sara Tolaney, including the following topics: Optimizing the Management of Localized HER2-Positive Breast Cancer Introduction (0:00) Case: A woman in her mid 60s with pulmonary hypertension and triple-positive, node-positive infiltrating ductal carcinoma (IDC) after neoadjuvant TCHP and clinical complete remissi...

Featuring a slide presentation and related discussion from Dr Thomas Herzog, including the following topics: Keys to evaluating genetics in patients with ovarian cancer (0:00) Clinical trials evaluating PARP inhibitor maintenance therapy for patients with newly diagnosed ovarian cancer responding to platinum-based chemotherapy (7:35) Current status of PARP inhibitor use in the care of patients wit...

Featuring perspectives from Dr Thomas Herzog, including the following topics: Impact of PARP inhibitors (PARPi) on the care of patients with ovarian cancer (0:00) Clarifying the recent withdrawal of PARPi for treatment of recurrent or refractory ovarian cancer (4:13) Sequential use of PARPi for patients with advanced ovarian cancer (16:56) Case: Woman in her late 60s with BRCA wild type ovarian ca...

Emerging Role of Antibody‑Drug Conjugates in the Management of Non‑Small Cell Lung Cancer — Faculty Presentation 2: TROP2 and Other Investigational Targets for ADCs in Advanced NSCLC — Dr Alexander Spira CME information and select publications

Emerging Role of Antibody‑Drug Conjugates in the Management of Non‑Small Cell Lung Cancer — Faculty Presentation 1: Targeting HER2 and HER3 with Antibody-Drug Conjugates (ADCs) in Non-Small Cell Lung Cancer (NSCLC) — Dr Helena Yu CME information and select publications